Apogee Therapeutics Inc

What they do

Apogee is a clinical-stage biotechnology company developing novel antibody biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline includes zumilokibart (APG777), a subcutaneous anti-IL13 antibody with extended half-life, as well as combination programs APG279 (zumilokibart + APG990) and APG273 (zumilokibart + APG333), and APG808, a half-life extended IL-4R antibody. The company is conducting clinical trials, including the APEX Phase 2 trial for moderate-to-severe atopic dermatitis, and has reported positive interim results for APG808 in asthma. Apogee is not yet generating revenue.

Revenue drivers

• Product revenue — No approved products; the company is pre-commercial and generates no product revenue.
• Collaboration and acquisition — Under pending acquisition by AbbVie for $135.11 per share in cash, total equity value ~$10.9 billion, which is the likely source of shareholder value.
• Non-dilutive financing (Blackstone) — May 2026 strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to support Phase 3 development and potential commercialization of zumilokibart.

Recent performance

For Q2 2026, Apogee reported net losses: annual net income for 2024 was -$182.1M and for 2025 -$255.8M; diluted EPS for 2025 was -$4.22. As of June 30, 2026, total assets were $1.34B, total liabilities $141.2M, and cash & equivalents $105.6M. The company has no revenue, only R&D expenses. In May 2026, it announced positive 16-week induction dose optimization results from APEX Phase 2 Part B, meeting primary and secondary endpoints with statistical significance.

Strategy

Apogee is focused on advancing its pipeline, particularly zumilokibart, into Phase 3 development for moderate-to-severe atopic dermatitis, with initiation planned in 2026. It is also expanding into additional indications, including EoE (ELEVATE Phase 2a trial) and asthma (ASPIRE Phase 2b trial), expected to start in 2H 2026. The company entered into a financing collaboration with Blackstone Life Sciences to support development without future equity financing. Pending acquisition by AbbVie aims to leverage AbbVie's scientific expertise, global scale, and commercial capabilities to realize the full potential of the programs worldwide.

Risks

• Clinical trial risk — Product candidates are in development; safety and efficacy are not yet established by regulatory authorities, and later-stage trials may fail.
• Acquisition closing risk — The AbbVie acquisition is subject to customary closing conditions, including shareholder approval and regulatory approvals; if it fails, the company's stock price could decline.
• Financing and cash burn — The company has no revenue and sustained net losses ($255.8M in 2025); although Blackstone financing provides up to $1.3B, it may not be sufficient if timelines slip.
• Regulatory and competitive — The I&I market is competitive with existing standard-of-care therapies, and regulatory approval for new biologics is uncertain and time-consuming.

Outlook

Management expects to initiate Phase 3 trials for zumilokibart in moderate-to-severe atopic dermatitis in 2026, based on positive APEX Part B results. The ELEVATE Phase 2a trial in EoE is expected to initiate in 2H 2026, and the ASPIRE Phase 2b trial in asthma is also planned. The acquisition by AbbVie is expected to close in the third quarter of 2026, subject to conditions.